Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of stem cells selection technology, today announces that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraft.

The trial is intended to assess the Cellect ApoGraft process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient's body cells and organs. GvHD is a life-threatening condition occurring in up to 50% of stem cell transplants. In this trial, the company will be testing stem cells transplanted from a matched donor related to the patient.

Referring to the trial on healthy volunteers, the company plans to release definitive and complete results of this trial before the end of Q1 this year.

Cellect CEO, Shai Yarkoni commented, Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide. ApoGraft has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies. I am excited with prospects of Cellect becoming a key contributor to the fast-growing market for stem cells based products enabling 21st century regenerative medicine.

The study is being conducted at the Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel. The primary objective of the trial is to assess the safety and tolerability of ApoGraft administered to patients with hematological malignancies undergoing allogeneic stem cell transplantation from a matched related donor.

View original post here:
Cellect Biotechnology (APOP) Says It Treated First Blood Cancer Patient in Phase I/II Trial of ApoGraft - StreetInsider.com